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Abstract Infantile and juvenile neuronal ceroid lipofuscinosis
(NCLs) are progressive neurodegenerative disorders of child-
hood with distinct ages of clinical onset, but with a similar
pathological outcome. Infantile and juvenile NCL are inherited
in an autosomal recessive manner due to mutations in the CLN1
and CLN3 genes, respectively. Recently developed Cln1- and
Cln3-knockout mouse models share similarities in pathology
with the respective human disease. Using oligonucleotide arrays
we identi¢ed reproducible changes in gene expression in the
brains of both 10-week-old Cln1- and Cln3-knockout mice as
compared to wild-type controls, and con¢rmed changes in levels
of several of the cognate proteins by immunoblotting. Despite
the similarities in pathology, the two mutations a¡ect the ex-
pression of di¡erent, non-overlapping sets of genes. The possible
signi¢cance of these changes and the pathological mechanisms
underlying NCL diseases are discussed.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Gene expression pro¢ling in disease can furnish information
on the pathogenesis of the disease at the molecular level and
provide potential markers for disease progression. We report
the use of high-density oligonucleotide arrays to examine the
mRNA pro¢le for approximately 36 000 genes in the brain of
mouse models for two types of childhood neurodegenerative
disorders: infantile and juvenile neuronal ceroid lipofuscinosis
(NCL). Both infantile (INCL) and juvenile NCL (JNCL) are
inherited in an autosomal recessive manner; JNCL represents
the most common type of progressive neurodegenerative dis-
ease in children. JNCL is characterized initially by visual de-
terioration at age 5^7 years that ultimately results in blind-
ness, followed by an increased frequency of seizures, mental
retardation, loss of motor skills and premature death [1,2].
INCL has a similar course, but has onset before 2 years of
age. The CLN1 and CLN3 genes were identi¢ed in 1995 [3,4].
The CLN1 gene encodes a palmitoyl-protein thioesterase
(PPT1) that is involved in the lysosomal metabolism of fatty
acylated proteins [5]. The CLN3 gene encodes a transmem-
brane protein of unknown function, most likely localized to
the late endosome/lysosome in non-neuronal cell types and
possibly in synaptic vesicles in neurons, reviewed in [6]. In
both INCL and JNCL, auto£uorescent hydrophobic material
accumulates in the lysosomes of neurons and other cell types.
However, the major component of the storage material is
di¡erent in each disease type. In INCL the major component
of the lysosomal storage material has been identi¢ed as sap-
osins A and D [7]. Since saposins A and D are not PPT1
substrates, and because these proteins are also elevated in
other lysosomal disorders, their accumulation may represent
a thematic pathology resulting from lysosomal dysfunction. In
JNCL, a predominant component of the lysosomal storage
material has been identi¢ed as mitochondrial ATP synthase
subunit c [8^11]. One of the paradoxes of NCL-disease is that
the accumulation of this lysosomal storage material does not
apparently lead to disease in non-neuronal cell types. More-
over, how these cellular alterations relate to the neurodegen-
eration in NCL-disease is unknown. Both the CLN1 and
CLN3 proteins have been localized to late endosomes and
lysosomes in non-neuronal cell types [12^14].
Cln1-knockout mice homozygous for a truncation of the
CLN1 gene product have been previously reported to have
characteristic accumulation of auto£uorescent material in
the CNS and to have neurologic abnormalities [15]. Cln3-
knockout mice homozygous for a targeted deletion of exons
1^6 in the Cln3 gene have been previously reported to show
characteristic accumulation of auto£uorescent lipopigments
containing mitochondrial ATP synthase subunit c in neural
tissue, and selective loss of GABAergic neurons [16]. At 10
weeks of age both Cln1- and Cln3-knockout mice show evi-
dence of storage material, but no reported evidence of behav-
ioral or neurologic dysfunction. To explore changes in gene
expression that precede these degenerative changes, we have
used high-density oligonucleotide arrays to compare the ex-
pression of approximately 36 000 transcripts in the brain of
10-week-old Cln1-, Cln3-knockout and wild-type control mice.
Reproducible, but distinct changes in expression were evident
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in both Cln1- and Cln3-knockout mice, as compared to nor-
mal, suggesting that there is a di¡erence in the molecular
mechanisms that underlie INCL and JNCL, respectively.
This data-set provides an important illustration as to what
may be occurring at the molecular level in the brain of ho-
mozygous Cln1- and Cln3-knockout mice that undergo neuro-
degeneration as a result of lacking functional CLN1 and
CLN3 protein, respectively.
2. Materials and methods
2.1. Animals
Ten-week-old wild-type control C57BL6J/129S6/SvEv and homozy-
gous Cln1-knockout mice on the same mixed background [15], and
10-week-old wild-type control 129S6/SvEv and homozygous Cln3-
knockout mice on a 129S6/SvEv background [16] were used for this
study. All procedures were carried out in accord with NIH guidelines
and the University of Rochester Animal Care and Use Committee
Guidelines.
2.2. Gene expression studies and data analysis
For comparative gene expression studies, whole brain from three
10-week-old wild-type control and CLN3-knockout mice (or similarly,
wild-type and CLN1-knockout mice) were pooled, respectively, and
homogenized by standard procedures in Trizol (Gibco BRL) for
mRNA extraction. Total RNA from each sample was used to gener-
ate a high-¢delity cDNA, which is modi¢ed at the 5P-end to contain
an initiation site for T7 RNA polymerase as per the manufacturer’s
protocol (SuperChoice, Gibco BRL). Upon completion of cDNA syn-
thesis 1 Wg of product was used in an in vitro transcription (IVT)
reaction that contained biotinylated UTP and CTP, which are utilized
for detection following hybridization to the microarray as per the
manufacturers protocol (ENZO). Full-length IVT product (20 Wg)
was subsequently fragmented in 200 mM Tris^acetate (pH 8.1),
500 mM KOAc and 150 mM MgOAc at 94‡C for 35 min. Following
fragmentation all components generated throughout the processing
procedure (cDNA, full-length cRNA, and fragmented cRNA) were
analyzed by gel electrophoresis to assess the appropriate size distribu-
tion prior to microarray analysis.
Gene expression was analyzed using the A¡ymetrix U74 high-den-
sity oligonucleotide array set at the University of Rochester Micro-
array Core Facility. Each gene on the array is represented by 16^20
pairs of 25 mer oligonucleotides that span the coding region for each
gene represented. Each probe pair consists of a perfect match se-
quence that is complementary to the cRNA target and a mismatch
sequence that has a single base pair mutation in a region critical for
target hybridization; this sequence serves as a control for non-speci¢c
hybridization. Hybridization, staining and washing of all arrays was
performed in the A¡ymetrix £uidics module as per the manufacturer’s
protocol. Streptavidin phycoerythrin stain (Molecular Probes) was the
£uorescent conjugate used to detect hybridized target sequences. De-
tection and quanti¢cation of target hybridization was performed with
a GeneArray Scanner (Hewlett Packard/A¡ymetrix) set to scan each
array twice at a factory set photomultiplier tube (PMT) level and
resolution. All arrays were scanned pre- and post-antibody ampli¢ca-
tion with respect to the dynamic range of the scanner. Several genes
have been identi¢ed on each array to help assess the overall quality of
signal intensity from all arrays. The result of this analysis has dem-
onstrated that all arrays are within a 0.2-fold di¡erence of each other
at baseline.
The Microarray Analysis Suite version 5 (A¡ymetrix) was employed
to generate the comparative analysis presented in this study. Algo-
rithms were used as described with thresholds set to default levels as
de¢ned by the manufacturer. All arrays within this data-set were
normalized via global scaling (target intensity= 2500), and Super
Scoring (SDT=3) was applied to all probe sets of eight probe pairs
or more, meaning that any probe pairs average di¡erence that ex-
ceeded 3 standard deviations of the mean of all probe sets was not
calculated in the average di¡erence metric. All data represented are
from the average of all pair-wise comparisons in the same direction.
2.3. RT-PCR
Ampli¢cation of a portion of each gene was performed using ap-
proximately 0.4 Wg total RNA extract using a Life Technologies
SuperScript One-Step RT-PCR system, according to the manufactur-
er’s guidelines. Primers used for ampli¢cation were: GAPDH, 5P-AC-
CACAGTCCATGCCATCAC-3P and 5P-TCCACCACCCTGTTGC-
TGTA-3P ; AI505387, 5P-GTTATTGGCTACACCAATTAAAAC-3P
and 5P-TGTTGTAAAACGCATGAGG-3P
2.4. Immunoblot analysis
Whole-brain extracts from 10-week-old wild-type control and
CLN3 knockout mice were prepared in ice-cold 50 mM sodium phos-
phate bu¡er containing 0.5 mM dithiothreitol (DTT; pH 7.5) using
pellet pestles. Protease inhibitor cocktail (Sigma, catalog No. P27140)
was added to the samples to a ¢nal concentration of 2U. Following
homogenization on ice, an equal volume of 50 mM sodium phos-
phate, 0.5 mM DTT, and 0.2% SDS (pH 7.5) was added and samples
were centrifuged at 13 000 rpm for 5 min at 4‡C to remove cellular
debris. Proteins (10 Wg) were separated on a 13% SDS^PAGE gel.
Immunoblotting was performed using a primary COMT antibody at
a 1:5000 dilution (BD Transduction) and the secondary antibody
(horseradish peroxidase-conjugated anti-mouse IgG) at 1:3500 dilu-
tion. Immunodetection was performed with an ECL-PLUS kit (Amer-
sham-Pharmacia Biotech, Piscataway, NY, USA) as per the manufac-
turer’s instructions. Similar procedures were used for immunoblotting
of Cln1-knockout mice with the exception that 50 Wg of protein was
loaded per lane and immunoblotting was performed using a commer-
cially (Promega, Cat. No. G5601) available antibody directed against
glial ¢brillary acid protein (GFAP) or with a mouse monoclonal anti-
body directed against platelet activating factor acetylhydrolase-2
(PAFAH2) (a kind gift of Dr. Hiroyuki Arai, University of Tokyo).
3. Results and discussion
Gene expression was assessed in the whole brain of 10-
week-old mice to explore changes in transcription that may
precede degenerative changes. Whole brains were collected
from three 10-week-old male Cln1- and Cln3-knockout and
three age-matched male wild-type control mice for each
Table 1
Annotated list of genes with altered expression of greater than 1.5
in whole brain of Cln1-knockout mice as compared to wild-type
controls
Fold change Accession # Annotation
5.81 AW259399 Platelet activating factor
acetyl hydrolase 2
5.11 AI845935 G-protein L-1 subunit
3.99 AI505203 IAP1
3.9 X02801 GFAP
2.79 AU017193 Unknown
2.33 AW122659 Similar to K-2-adrenergic
receptor
2.28 U29055 G-protein L-36 subunit
2.27 AI848373 Unknown
2.08 AV274188 Unknown
1.97 AI837340 VAMP3
1.77 AA606998 Similar to zinc ¢nger
protein 97
1.63 AI851048 RAB6
34.27 AI505387 Unknown
33.19 U65592 Kþ-channel, L-subunit
32.77 AA874329 Unknown
32.4 AV150568 Unknown
32.08 AI849615 GAS5
31.92 AV848986 Unknown
31.9 AW125152 Six3
31.56 AI837101 Calsyntenin-1
Fold change in expression evident in a nine-ways comparison, each
wild-type (n=3) compared to each Cln1-knockout (n=3). Statistical
signi¢cance for each change reported has a P-value of 6 0.05 by a
standard t-test performed in Microarray Suite 5. List derived from
genes that had an increase or decrease in expression of 1.5 or more.
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knockout model, and the material from each genotype was
pooled together for extraction of mRNA. We analyzed age-
matched Cln1- and Cln3-knockout and wild-type control
mice. To average out variability among animals and litters,
for each genotype RNA was prepared from three pools of
three brains each. Expression values for wild-type were com-
pared pairwise with those for knockout, giving nine compar-
isons for Cln1 and 9 for Cln3. Tables 1 and 2 present the fold
changes s 1.5 and with P6 0.05 according to a t-test per-
formed in Microarray Suite 5 (A¡ymetrix). A full data-set
reporting all genes, sorted into functional categories, with ex-
pression changes of 1^1.5 with a P-value of 6 0.05 is available
at http://dbb.urmc.rochester.edu/labs/pearce/microarray.html.
3.1. Altered gene expression in Cln1-knockout brain
Table 1 shows a list of genes that showed altered expression
(1.5-fold or more) in 10-week-old Cln1-knockout mouse brain
as compared to normal. A previous study of Cln1-knockout
mice [15] showed that the mean time to the development of
neurological abnormalities was 21 weeks, and that only 10%
of mice demonstrated spasticity at 10 weeks of age, the age at
which the current study was performed. It is interesting that
relatively few genes showed altered expression, which presum-
ably re£ects the pre-symptomatic state. The types of genes
with altered expression in the Cln1-knockout brain provide
potential insights into the molecular mechanisms that are al-
tered. For example, the most highly up-regulated gene in the
Cln1-knockout brain was PAFAH2, an enzyme of potential
interest for two reasons. Firstly, it is a lipase with a rather
broad substrate speci¢city, not unlike PPT1. Therefore, there
is a possibility that PAFAH2 is up-regulated in response to
the accumulation of lipid substrate, and a role for PAFAH2
in compensating partially for the de¢ciency of PPT1 can be
envisioned. Secondly, PAFAH2 has been shown to translocate
to cell membranes in response to oxidative stress, where it is
believed to function in the removal of oxidized fatty acids
from oxidatively damaged phospholipids [17]. Oxidative stress
has been considered a potential contributor to the pathophys-
iology of lipofuscin accumulation (reviewed in [18]). We have
further shown that fatty acyl cysteine thioesters accumulate in
the lysosomes of PPT-de¢cient cells [19]. It is possible that the
undigested fatty acids eventually become oxidized upon pro-
longed storage in the environment of the lysosome, and even-
tually make their way into PAFAH2 metabolic pathway. The
Table 2
Annotated list of genes with altered expression of greater than 1.5
in whole brain of Cln3-knockout mice as compared to wild-type
controls
Fold change Accession # Annotation
7.32 AI505387 Unknown
5.7 AV148864 Unknown (similar to M5-14)
3.87 AI835219 G-protein Q-4 subunit
2.32 AA681694 Possible RNA binding protein
2.3 X04097 RP2, androgen regulated protein
1.96 AV371646 Unknown
1.92 AW209050 Unknown (similar to human
FLJ23151)
1.85 AW122327 Similar to laminin L-2.
34.43 AA015150 PRK2, lipid activated kinase
33.56 AF076156 COMT
33.19 AW046827 Unknown
32.01 AI848384 Glutamine synthetase
31.78 AV004774 mGluR3
31.5 AI843865 Similarity to acetylcholinesterase
Fold change in expression evident in a nine-ways comparison, each
wild-type (n=3) compared to each Cln3-knockout (n=3). Statistical
signi¢cance for each change reported has a P-value of 6 0.05 by a
standard t-test performed in Microarray Suite 5. List derived from
genes that had an increase or decrease in expression of 1.5 or more.
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Fig. 1. Immunoblotting and densitometric quantitation shows that
(A) PAFAH2 and (B) GFAP are elevated in Cln1-knockout mouse
brain, as compared to wild-type (WT) mouse brain. 50 Wg of pro-
tein from Cln1-knockout or wild-type brain was analyzed in each of
six independent experiments with protein extracted from six brains
per experiment. The average signal for wild-type was set to 1, and
the error bars indicate the standard error.
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up-regulation of PAFAH2 protein was con¢rmed by immu-
noblotting, as shown in Fig. 1, panel A.
It is interesting that mRNAs for both VAMP3 and RAB6
are up-regulated. Both VAMP3/cellubrevin and Rab6 were
recently shown to play rather speci¢c roles in tra⁄cking of
proteins from early endosome/recycling endosomes to the
trans-Golgi network [20]. The signi¢cance of this ¢nding re-
mains to be elaborated, but it is likely that dysfunction in one
compartment (the lysosome) may have an impact on tra⁄ck-
ing in others. Up-regulation of GFAP mRNA is very consis-
tent with the glial cell proliferation that has been well-de-
scribed in INCL. Immunoblotting for GFAP (Fig. 1, panel
B) shows that the protein levels are up-regulated as well. Up-
regulation of the G-protein L-1 subunit (same transcript as
G-protein L-36 subunit) at the protein level was not con¢rmed
(data not shown). The up-regulation of IAP1 (inhibitor of
apoptosis-1) is potentially interesting, because widespread
neuronal apoptosis was demonstrated in CLN1 knockout
mice [14]. We performed immunoblots to examine IAP1 levels
in CLN1 knockout and control mouse brains, but found a
great deal of variability in the signal intensity from sample
to sample regardless of genotype. IAP1 is regulated in cells by
proteolysis and not much is known concerning the role of
transcription in its regulation. It is likely that our ¢nding is
important but more work will be necessary to better under-
stand the role of IAP1 in INCL and in neurodegenerative
disease in general.
Down-regulation of several known genes in CLN1 knock-
outs was observed (Table 1). One of these is a neural-speci¢c
Kþ channel L-subunit. The function of this subunit is to en-
hance expression of the K-subunit, Kv2.2, a Shab Kþ channel
[21]. Other down-regulated transcripts include GAS5, a non-
coding growth arrest-speci¢c gene involved in the processing
of rRNAs [22], and Six3, a transcription factor important in
the development of the eye and forebrain [23]. Also down-
regulated was calsyntenin-1, a newly described transmem-
brane protein with a cytoplasmic calcium binding domain
localized to the postsynaptic membrane of both excitatory
and inhibitory synapses [24]. Its down-regulation may merely
re£ect neuronal loss. However, since few neuron-speci¢c genes
were identi¢ed at this early time, it is more likely that the
regulation is speci¢c and warrants further investigation.
It may also be of interest that the most down-regulated
gene in CLN1 knockout mice corresponded to an unknown
transcript (AI505387) that was the most highly up-regulated
gene in CLN3 knockout mice (see below).
3.2. Altered gene expression in Cln3-knockout brain
Table 2 shows those genes that have increased or decreased
expression of 1.5 or more in Cln3-knockout mice brain com-
pared to normal. It is interesting that gene products with
altered expression in Cln3-knockout mice brain that have a
known function are associated to neurotransmitter metabo-
lism. Two genes associated with glutamate utilization, namely
glutamine synthetase which converts glutamate to glutamine
and the glutamate receptor mGluR3 are down-regulated.
Down-regulation of genes associated to glutamate utilization
has been previously reported, and veri¢ed at the protein level
in the cerebellum of Cln3-knockout mice due to the presence
of an autoantibody to GAD65 which inhibits conversion of
glutamate to GABA and therefore leads to an accumulation
of glutamate [25,26]. This report indicates that the e¡ect of
the autoantibody on glutamate levels occurs throughout the
brain, and may be a contributory factor to loss of GABAergic
neurons in Batten disease [16,25]. Down-regulation of cate-
chol-o-methyltransferase (COMT) is also apparent in the
whole brain (Table 2), suggesting that metabolism of dopa-
mine is altered in the Cln3-knockout mouse. We have veri¢ed
that COMT protein levels are in fact decreased in whole brain
of Cln3-knockout mice as compared to normal, as shown in
Fig. 2. The decrease in COMT-protein levels may be linked to
a recent report demonstrating a lower density of striatal do-
pamine D1 receptors in patients with JNCL [27], by way of an
underlying disruption in dopamine neurotransmission. Other
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Fig. 2. Immunoblotting and densitometric quantitation shows that
COMT is decreased in Cln3-knockout as compared to wild-type
(WT) mouse brain. A: Membrane bound (MB)-COMT. B: Soluble
(S)-COMT in protein extracts from wild-type and Cln3-knockout
mice. 10 Wg of protein from Cln3-knockout or wild-type brain was
analyzed in each of six independent experiments with protein ex-
tracted from six brains per experiment. The average signal for wild-
type was set to 1, and the error bars indicate the standard error.
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imaging studies in JNCL patients reported decreases in £uo-
rodopa uptake [28] as well as in dopamine transporter binding
[29], indicating that there may be multiple aspects in which
dopaminergic function is perturbed. Disruptions in dopamine
neurotransmission have been associated to Parkinson’s dis-
ease, and implicated in various neuropsychiatric disturbances,
components of both of which have similar manifestations in
patients during the course of JNCL. In addition, acetylcho-
linesterase is also down-regulated in Cln3-knockout brain sug-
gesting that there may be a disturbance in acetylcholine levels
which also could be a contributor to neurological abnormal-
ities in Batten disease.
3.3. Comparative analysis of gene expression changes between
Cln1- and Cln3-knockout mice
In comparing the genes that have altered expression in
Cln1- to Cln3-knockout mice brain there are two salient ob-
servations. First, there is little overlap between the two NCL-
mouse models in the changes seen. Therefore the pre-sympto-
matic changes at the molecular level are di¡erent in Cln1- to
Cln3-knockout mice and is strongly suggestive that despite
many similarities, the molecular basis for the pathology of
INCL and JNCL is distinct. The second signi¢cant observa-
tion is that the gene showing the highest degree of down-
regulation in the Cln1-knockout (unknown gene, accession #
AI505387) is the most highly up-regulated transcript in the
Cln3-knockout. We have validated this observation by semi-
quantitative RT-PCR, shown in Fig. 3. The signi¢cance of
this observation awaits identi¢cation of the function of this
uniquely regulated gene.
Lysosomal storage diseases such as the NCLs typically re-
sult in neurological disease. It would therefore be interesting
to compare gene expression changes reported in this study
that are present in other mouse models for lysosomal storage
disease, such as those reported for Sandho¡ disease which
highlighted the in£ammatory response in this disease [30],
and others when they become available. Such an approach
would be useful in de¢ning the molecular processes that are
disturbed as a result of lysosomal storage in the brain, and
also as in this study, in delineating disease-speci¢c alterations
at the gene expression level.
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